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Pseudoginsenoside-F11(PF11),acomponentofPanaxquinquefolism(Americanginseng),playsalotofbeneficialeffectsondisorders
o fc e n traln e rv o u ssy s t e m.I nthi spa pe r ,th en e ur o p r o t ecti v ee ff ecto fP F11o nP a r kin so n ’ sdi sea se(P D )a n dth epos si b lem ec h a ni sm
were investigated in a rat PD model. PF11 was orally administered at 3, 6, and 12mg/kg once daily for a period of 2 weeks before
and 1 week after the unilateral lesion of left medial forebrain bundle (MFB) induced by 6-hydroxydopamine (6-OHDA). The
results showed that PF11 markedly improved the locomotor, motor balance, coordination, and apomorphine-induced rotations
in 6-OHDA-lesioned rats. The expression of tyrosine hydroxylase (TH) in substantia nigra (SN) and the content of extracellular
dopamine (DA) in striatum were also significantly increased after PF11 treatment. Moreover, significant reduction in the levels of
striatal extracellular hydroxyl radical (
∙OH), detected as 2,3- and 2,5-dihydroxy benzoic acid (2,3- and 2,5-DHBA), and increase
in the level of striatal extracellular ascorbic acid (AA) were observed in the PF11-treated groups compared with 6-OHDA-lesioned
rats. Taken together, we propose that PF11 has potent anti-Parkinson property possibly through inhibiting free radical formation
and stimulating endogenous antioxidant release.
1. Introduction
Parkinson’s disease (PD), the second most common progres-
sive neurodegenerativedisorder, is characterized by degener-
ation of dopaminergic neurons in the nigrostriatal pathway
and subsequent dopamine (DA) depletion in the striatum
[1]. Although various mechanisms of neuronal degeneration
in PD have been proposed, the exact pathogenesis of PD is
not well understood [2, 3]. Increasing studies have demon-
strated that one of etiologies about PD is the imbalance
between free radical formation and the maintenance of the
dopaminergic neuronal integrity through the endogenous
antioxidant defense system [4–6]. Ascorbic acid (AA), one
of the important antioxidants in the endogenous antioxidant
defense system, is thought to play a major role in protecting
brain against oxidative damage. It has been reported that
the level of plasma AA in PD patient is significantly lower
than that in healthy control subject [7]. The previous study
in our lab has also proved that release of endogenous AA in
the striatum plays an important role in preventing oxidative
stress by trapping 2,3- and 2,5-dihydroxy benzoiclacid (2,3-
and2,5-DHBA)thatreflectedthehydroxyradical(
∙OH)level
[8]. It is suggested that AA as an antioxidant may be benefit
to PD and be worth further study.
Many experiments have demonstrated that ginseng
extracts exert anti-Parkinson effect [9–12]. The previous
studies have shown that Pseudoginsenoside-F11 (PF11), an
ocotillol-type saponin isolated from leaves of Panax pseu-
doginseng subsp. Himalaicus Hara (Himalayan Panax), but
not in Panax ginseng, plays an important role in treating
many disorders of the central nervous system, such as
antioxidation [13], antagonistic actions on morphine and
methamphetamine [14–17], and antiamnesic effect [13, 18].
PF11 shows the similar effect to ginsenosides isolated from
Panax ginseng. Moreover, PF11 is proved to antagonize the
decrease of DA in the brain of methamphetamine-treated
mice in our previous studies [16]. Considering the improve-
ment of PF11 on DA levels and its antioxidation, it is well2 Evidence-Based Complementary and Alternative Medicine
worthytoinvestigatewhetherPF11,likeginsengsaponins,has
an antagonistic effect on PD and whether the mechanism is
associated with its antioxidative activity.
In the present study, the antagonistic effect of PF11 on 6-
OHDA-induced rats of PD model was investigated by using
four kinds of behavioral tasks. The level of extracellular
DA in striatum and the expression of tyrosine hydroxylase
(TH) in substantia nigra (SN), a rate limiting enzyme in the
biosynthesis of DA, were also investigated. Furthermore, the
p r o t e c t i v em e c h a n i s mo fP F 1 1o nP Dw a sa l s oe x p l o r e db y
measuring the changes of AA and 2,3- and 2,5-DHBA release
in striatum.
2. Materials and Methods
2.1. Animals. Male Sprague-Dawley rats weighting 200–
250g were supplied by the Experimental Animal Centre
of Shenyang Pharmaceutical University and kept with a
12hL:12hD light/dark cycle (light on at 06:30 am). Rats
were housed in cages with food and water freely available.
All experiments and procedures were carried out according
to the Regulations of Experimental Animal Administration
issued by State Committee of Science and Technology of
China.
2.2. Chemicals. PF11 was isolated from the aerial parts of
P. quinquefolism by the Department of Chemistry for Nat-
ural Products of Shenyang Pharmaceutical University. The
purity was more than 98% as determined by HPLC. PF11
was dissolved in distilled water before administration. 6-
OHDA, apomorphine, salicyliclacid (SA), and its hydroxy-
lated derivatives, 2,3-DHBA and 2,5-DHBA, were purchased
from Sigma Chemicals (St. Louis, MO, USA). 6-OHDA
was dissolved in saline containing 0.1% AA and prepared
freshly in dark to avoid autooxidation. Apomorphine was
d i s s o l v e di ns a l i n e .M a d o p a rw a sp u r c h a s e df r o mS h a n g h a i
Roche PharmaceuticalsLtd.Ringer’ssolution(NaCl147mM,
KCl 4 mM, and CaCl2 2.3mM) contains 2mM salicylate as
hydroxyl radical trapping reagent [8]. All other chemicals
were commercially available and of reagent grade.
2.3. Animal Grouping and PF11 Treatment. The animals were
divided into 6 groups (6 rats in each group): sham group,
6-OHDA-lesioned group, PF11-treated groups (3, 6, and
12mg/kg), and Madopar-treated group (50mg/kg). PF11 and
Madopar were orally administered once daily for 3 weeks.
2.4. 6-OHDA Lesion. Two weeks after PF11 and Madopar
treatment, the left medial forebrain bundle (MFB) was
l e s i o n e db y6 - O H D A .Th er a t sw e r ea n e s t h e t i z e dw i t h
chloral hydrate (350mg/kg, i.p.) and fixed in a stereotaxic
instrument. Lesions were made by injecting 6-OHDA (20𝜇g
in saline containing 0.1% AA) into the left MFB at the
coordinate: 𝐴, −2.5; 𝐿, −2.0; 𝑉, −8.5mm, from bregma using
a5𝜇L Hamilton syringe at a rate of 1𝜇L/min [19]. The sham
animals were injected vehicle only (0.1% AA-saline) at the
same coordinate. After injection, the syringe was left in place
for an additional 5min before being slowly retracted. 6-
O H D Aa n ds h a mr a t sw e r eh o u s e do n ew e e kf o rf u r t h e r
experiments.
2.5.BehavioralStudies. Oneweekafterinjectionof6-OHDA,
animals were subjected to behavior testing, which were,
respectively, spontaneous locomotor activity test, rotarod
test, narrow beam test, and apomorphine-induced circling
test.
2.5.1. Spontaneous Locomotor Activity. The spontaneous
locomotor activity of rat was analyzed with a video-tracking
system EthoVision (Noldus, Wageningen, NL) [20]. Two
animals were placed into neighboring “home” cages under a
video camera, respectively. Using the video-tracking system
EthoVision, motor behavior was recorded during the moni-
toring for 5min. The “total distance” (total distance traveled
by the animal during the 5min observation time, in cm) and
the“meanvelocity”(meanofthevelocitiesofall0.2speriods
d u r i n gt h e5m i no b s e rv a t i o nt i m e ,i nc m / s )w e r em e a s u r e d .
2.5.2. Rotarod. Rotarod was used for the study of muscular
coordination. It consisted of a rotating rod, 75mm in diam-
eter, which was divided into four parts by compartmental-
ization to permit the testing of four rats at a time. The time
for each rat to remain on the rotating rod was recorded. The
speed was set at 10 cycles per min and cut-off time was 180s.
Theanimalsofallgroupsweretrainedonrotarodpriorto the
start of the experiment until they could stay on it at least for
the cut-off time. After 1 week of lesioning, the rats of each
group were tested on rotarod [21].
2.5.3. Narrow Beam Test. After 1 week of lesioning, the rats
were tested for the balance and motor coordination on a nar-
row beam. The narrow beam had a smooth wooden narrow
beam of 105cm in length, 4cm in width, and thickness of
3cm. The beam was elevated from the ground by 1m with
additionalsupports.Ithadagoalboxattheendofthenarrow
beam. There was food in the goal box for the reward of the
animals. The rats were trained on the narrow beam for 10
trialsperdaywith1mininterval.Theanimalswereallowedto
explore the narrow beam for 10 trials with 1min interval on 1
day before the experimental day and during this exploration
ratsweremotivatedandrewardedwithfoodpelletsinthegoal
box. The time to cross the beam was calculated [21].
2.5.4. Apomorphine-Induced Circling Behavior. The behavior
was assessed by monitoring body rotations induced by
intraperitoneal injection (i.p.) of apomorphine (0.5mg/kg).
The number of contralateral rotations was recorded for
30min [22].
2.6. Neurochemical Studies
2.6.1.BrainMicrodialysis. Afterbehavioraltests,theratswere
anesthetizedwithchloralhydrate(350mg/kg,intraperitoneal
injection) and the dialysis probes (310𝜇m o.d., 200𝜇m
i.d., AN69, Hospal, Dasco, Bologna, Italy) were implantedEvidence-Based Complementary and Alternative Medicine 3
through the striatum according to the following coordinates:
𝐴 +1.0mm from bregma, 𝑉−5.6mm from occipital bone.
The procedure used to prepare and implant the dialysis
p r o b ew a st h es a m ea sp r e v i o u s l yd e s c r i b e d[ 23]. Twenty-
four hours after implantation, the rats were perfused with
ringer’s solution containing 2mM salicylate as
∙OH trapping
reagent by means of a microinjection pump with a constant
rate of 2𝜇L/min. The first 1h samples for equilibrium were
discarded and then the dialysate was collected for 20min.
Twenty microliters of each collected sample was used for
analysis of the levels of AA, while twenty microliters of each
c o l l e c t e ds a m p l ew a su s e df o ra n a l y s i so fD H B Al e v e l s[ 8].
A n o t h e rg r o u po fa n i m a l sw e r eu s e dt oc o l l e c tt h ed i a l y s a t e
for DA determination. When the experiment was finished,
rat was sacrificed for checking the position of the dialysis
fiber. The datum was discarded if the fiber was positioned
incorrectly [24].
2.6.2. Assay for DA. The level of extracellular DA was
determined by high performance liquid chromatography
with electrochemical detection (HPLC-ECD) in accordance
with a previously described method [25]. This system used
a reverse phase column (C-18, 5𝜇m, Agilent) with a mobile
p h a s ec o m p o s e do f8 5m Mc i t r a z i n i ca c i d ,1 0 0m Ms o d i u m
acetate anhydrous, 0.2mM Na2EDTA, and 1.2mM sodium
1-octanesulfonate adjusted to pH 3.7 [25]. The mobile phase
was pumped with LC-10A pump (Shimadzu, Japan) at a flow
rate of 1.0mL/min. The electrochemical detector (L-ECD-
6A, Shimadzu, Japan) was set at +0.70 V. All the mobile
phases were filtered through a 0.22𝜇mfi l t e r .Th ec o l u m n
temperature was maintained at 37
∘C.
2.6.3. Assay for AA. The content of extracellular AA was
measured using method that has been described by Liu et
al. [26]. HPLC-ECD and a reverse phase column (C-18,
5𝜇m,Agilent)were usedwiththemobilephase composedof
155.6mM NaCl, 0.54mM EDTA-Na2,a n d1 . 5m Mt e t r a b u t y -
lammonium bromide as an ion pairing reagent. The flow rate
was 1.0 mL/min. The detector was set at +0.60V.
2.6.4. Assay for DHBA. The samples (20𝜇L) were injected
into HPLC system to detect the contents of 2,3, and 2,5-
DHBA to evaluate the
∙OH level. The mobile phase consisted
of 0.03M citrate, 0.03M acetate, and 10% methanol [8].
The equipment conditions were the same as that used for
detecting AA described above.
2.7. Immunohistochemical Study. Immunohistochemistry
was performed as previously described [27]w i t hm i n o r
modifications. The rats were anesthetized with chloral
hydrate (350mg/kg, i.p.) and perfused transcardially
through ascending aorta with 0.1M phosphate buffer saline
(PBS) at pH 7.4 followed by 4% paraformaldehyde in 0.1M
phosphate buffer. Brain was removed immediately and
fixed in the same fixative for an additional 24h at 4
∘C;
furthermore the tissues were preserved in 10%, 20%, and
30% sucrose solution (in PBS) until they sank. The fixed
tissues were embedded in OCT compound (polyvinyl
glycol, polyvinyl alcohol, and water) and frozen at −20
∘C.
Coronal sections of 20𝜇mt h i c k n e s s e sw e r ec u to nt h e
cryostat (Leica, Germany). The sections were rinsed three
times for 5min in PBS, and endogenous peroxidase activity
was blocked with 3% hydrogen peroxide in methanol and
incubated for 20min at room temperature. Slices were
permeabilized and blocked with PBS containing 1% Triton
X-100 and 4% normal goat serum, for 1h at 37
∘C. Thereafter,
the sections were incubated in primary antibody (anti-TH
mouse, 1:1000, Sigma) for 24h at 4
∘C, rinsed three times
for 5min in PBS, and subsequently incubated with avidin-
biotin-horseradish peroxidase conjugate (ABC Staining
System, Santa Cruz Biotechnology) for 1h. After washing,
theslideswereincubatedwithbiotinylatedrabbitanti-mouse
secondary antibody. The color was developed using DAB as
a chromogen. Finally, sections were dehydrated in graded
alcohol solutions, cleared in xylene, and coverslipped to
be viewed under a microscope and photo micrographs
were taken using a light microscope (Olympus BX 51,
Japan). Three sections per animal from the substantia nigra
were selected. The intensity of the TH immunoreactivity
at ×400 magnification was measured by semiquantitative
densitometric analysis using an image-analysis program
(Image-Pro Plus Version 6.0, Media Cybernetics, USA).
2.8. Statistical Analysis. Statistical analysis was carried out
by SPSS 13.0 software for windows (SPSS Inc., Chicago, IL,
USA). All values were expressed as mean ± S.E.M. Data were
analyzedviaone-wayanalysisofvariance(ANOVA)followed
by Dunnett’s 𝑡-test. Statistical significance was accepted at
𝑃 < 0.05.
3. Results
3.1. Neurobehavioral Studies
3.1.1.TheEffectofPF11ontheSpontaneousLocomotorActivity.
A ss h o w ni nF i g u r e1(a), one week after the 6-OHDA lesion,
the total distance was typically decreased in the 6-OHDA-
lesioned rats compared with the sham group (𝑃 < 0.001).
However, the decrease of total distance was significantly
blocked by PF11 (3, 6, and 12mg/kg) (𝑃 < 0.05). Figure 1(b)
s h o w e dt h a tas l o w e rm e a nv e l o c i t yi nt h e6 - O H D Al e s i o n e d
rats was observed (𝑃 < 0.001). There was significant increase
i nt h em e a nv e l o c i t yi nP F 1 1 - t r e a t e dg r o u p sc o m p a r e dw i t h
the 6-OHDA-lesioned group (𝑃 < 0.001). The mean velocity
was improved and almost returned to the level of sham
group after all of the doses of PF11 administration. These
data indicated that PF11 significantly improved the impaired
spontaneous locomotor activity in PD rats. Madopar-treated
group (50mg/kg) also showed improvement in total distance
a n dm e a nv e l o c i t y( 𝑃 < 0.05 and 𝑃 < 0.001).
3.1.2. The Effect of PF11 on the Muscular Coordination. The
rotarod test was used for the evaluation of muscular coor-
dination in the present study. A significant depletion (𝑃<
0.001) in muscular coordination in 6-OHDA-lesioned group
was observed as compared with sham group (Figure 2). PF114 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Effect of PF11 on spontaneous activity in 6-OHDA-lesioned rats. Results were means ± SEM of the data obtained in six rats per
group.
∗∗∗𝑃 < 0.001 compared to sham group;
#𝑃 < 0.05,
###𝑃 < 0.001 compared to 6-OHDA-lesioned group.
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Figure 2: Effect of PF11 on the muscular coordination in 6-OHDA-
lesioned rats. Results were means ± SEM of the data obtained in six
rats per group.
∗∗∗𝑃 < 0.001 compared to sham group;
#𝑃 < 0.05,
##𝑃 < 0.01,a n d
###𝑃 < 0.001 compared to 6-OHDA-lesioned
group.
(3, 6, and 12mg/kg) was found to be effective in recovery of
muscular coordination in a dose-dependent manner (𝑃<
0.05, 𝑃 < 0.01,a n d𝑃 < 0.001). The increase of muscular
coordination was also observed in Madopar-treated group
(50mg/kg) (𝑃 < 0.001).
3.1.3. The Effect of PF11 on the Motor Coordination. In the
present study, the rats were tested for the balance and motor
coordinationonthenarrowbeam.Thetimetakentocrossthe
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Figure 3: Effect of PF11 on the motor coordination in 6-OHDA-
lesioned rats. Results were means ± SEM of the data obtained in six
rats per group.
∗∗∗𝑃 < 0.001 compared to sham group;
##𝑃 < 0.01,
###𝑃 < 0.001 compared to 6-OHDA-lesioned group.
beam was significantly increased in 6-OHDA-lesioned rats
when compared with the sham group (𝑃 < 0.001). PF11 (3, 6,
and12mg/kg)markedlydecreasedthetimetakentocrossthe
beam in a dose-dependent manner (𝑃 < 0.001), indicating
that PF11 showed significant improvement in balance ability
(Figure 3). The increase of time taken to cross the beam was
shown in Madopar-treated group (50mg/kg) (𝑃 < 0.01).
3.1.4. The Effect of PF11 on the Rotation Induced by Apomor-
phine. RotationinducedbyapomorphinewasusuallyusedtoEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: Effect of PF11 on rotation behavior in 6-OHDA-lesioned
rats. Results were means ± SEM of the data obtained in six rats per
group.
#𝑃 < 0.05,
###𝑃 < 0.001 compared to 6-OHDA-lesioned
group.
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lesioned rats. Results were means ± SEM of the data obtained in six
rats per group.
∗∗𝑃 < 0.01 compared to sham group;
#𝑃 < 0.05,
###𝑃 < 0.001 compared to 6-OHDA-lesioned group.
behaviorallyassaytheextentofneuronallossfollowinglesion
by 6-OHDA. No rotation was observed in all rats in sham
group. Significant increases in the number of apomorphine-
induced rotations were observed in the 6-OHDA-lesioned
rats compared to the sham group (𝑃 < 0.001). As shown
in Figure 4, rats receiving PF11 (3, 6, and 12mg/kg) exhibited
significant attenuation (𝑃 < 0.001) in circling behavior, indi-
cating that PF11 significantly reversed this abnormal motor
behavior of 6-OHDA. The improvement of circling behavior
wasalsoobservedinMadopar-treatedgroup(50mg/kg)(𝑃<
0.05).
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Figure 6: Effect of PF11 on the release of striatal AA in 6-OHDA-
lesioned rats. Results were means ± SEM of the data obtained in six
rats per group.
∗∗𝑃 < 0.01, compared to sham group;
#𝑃 < 0.05,
###𝑃 < 0.001 compared to 6-OHDA-lesioned group.
3.2. Neurochemical Studies
3.2.1. The Effect of PF11 on the Level of Extracellular DA in
Striatum. The effect of PF11 on the level of extracellular DA
in the striatum was analyzed by using microanalysis coupled
with HPLC-ECD. The level of striatal extracellular DA was
lower in the 6-OHDA-lesioned group than that in the sham
group(𝑃 < 0.01).AdministrationofPF11(3,6,and12mg/kg)
significantly increased the level of striatal extracellular DA
in a dose-dependent manner (𝑃 < 0.05 and 𝑃 < 0.001)
(Figure 5) and PF11 (12mg/kg) significantly recovered the
level of striatal extracellular DA to the normal level. The
improvement of striatal DA was also shown in Madopar-
treated group when compared with 6-OHDA-lesioned group
(𝑃 < 0.001).
3 . 2 . 2 .Th eE ff e c to fP F 1 1o nt h eL e v e lo fE x t r a c e l l u l a rA A
in Striatum. AA was an important endogenous antioxidant
which was involved in cellular protection against damage
caused by oxidative stress. As presented in Figure 6,a
markedlylowerlevelofstriatalextracellularAAwasexhibited
in 6-OHDA-lesioned group compared to the sham group
(𝑃 < 0.01). The PF11-treated rats (6, 12mg/kg) attenuated the
6-OHDA-induced striatal extracellular AA depletion (𝑃<
0.05, 𝑃 < 0.001), indicating that PF11 could enhance the
antioxidant ability in striatum of PD rats. Madopar-treated
group (50mg/kg) also showed improvement in the level of
striatal extracellular AA (𝑃 < 0.05).
3 . 2 . 3 .Th eE ff e c to fP F 1 1o nt h eL e v e lo fE x t r a c e l l u l a rD H B A
in Striatum. In order to detect the effect of PF11 on the
level of extracellular DHBA in striatum, the levels of striatal
extracellular 2,3-DHBA and 2,5-DHBA, major products of
∙OHinteractedwithsalicylicacid,weredetected.Asshownin6 Evidence-Based Complementary and Alternative Medicine
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Figure7:EffectofPF11onthelevels ofstriatal2,3- and2,5-DHBAin6-OHDA-lesioned rats.Resultsweremeans±SEMofthedataobtained
in six rats per group.
∗𝑃 < 0.05,
∗∗𝑃 < 0.01 compared to sham group;
#𝑃 < 0.05,
##𝑃 < 0.01 compared to 6-OHDA-lesioned group.
Figures7(a)and7(b),thecontentsofextracellular2,3-DHBA
and 2,5-DHBA in striatum were significantly increased in
6-OHDA-lesioned group compared with sham group (𝑃<
0.05 and 𝑃 < 0.01). Following three weeks of treatment
with PF11, the increase of striatal extracellular 2,3-DHBA
was significantly inhibited by PF11 (3mg/kg) (𝑃 < 0.05)
(Figure 7(a)) and the increase of striatal extracellular of
2,5-DHBA was also significantly decreased by PF11 (3, 6,
12mg/kg) (𝑃 < 0.01, 𝑃 < 0.01,a n d𝑃 < 0.05). The
contents of 2,3-DHBA and 2,5-DHBA were decreased in
Madopar-treated group (50mg/kg) when compared to 6-
OHDA-lesioned group (𝑃 < 0.05, 𝑃 < 0.01).
3.3. The Effect of PF11 on the Expression of TH in SN. Just as
shown in Figure 8, immunohistochemical analysis showed
that a marked depletion in the expression of TH in the left
SN in 6-OHDA-lesioned group compared to the sham group
(𝑃 < 0.05)andapronouncedrestorationwereobservedinthe
PF11-treated groups (3, 6, and 12mg/kg) in a dose-dependent
manner (𝑃 < 0.05, 𝑃 < 0.001). Madopar (50mg/kg)
decreased the loss of TH immunoreactivity compared with
6-OHDA-lesioned group (𝑃 < 0.05). The result showed that
PF11 increased the number of dopaminergic neurons in PD
rats.
4. Discussion
Th er e s u l t so ft h i ss t u d yc l e a r l ys h o w e dt h a tt h ep r o t e c t i v e
e ff e c to fP F 1 1o nar a tm o d e lo fP Di si n d u c e db y6 - O H D A .I t
wasfoundthattreatmentwithPF11forthreeweeksimproved
performances in four kinds of behavior test, increased the
level of extracellular DA in striatum, and inhibited the
loss of DA neuron in SN. Because 6-OHDA can be easily
carried inside the dopaminergic neurons by the dopamine
transporter (DAT), it is thought to be one of the most
common neurotoxins used in degeneration models of the
nigrostriatal dopaminergic system, in vivo and in vitro [28–
30]. In this study, we used unilateral injection of 6-OHDA
into MFB to establish a rat model of PD which mimicked
behavioral,biochemical,andhistopathologicalabnormalities
observed in patients with PD [31].
In thepresentstudy, treatmentwithPF11at all3dosesfor
3weekssignificantlyimprovedtheabnormalbehaviorsinPD
rats induced by 6-OHDA, including the locomotion, muscle
and motor coordination, and contralateral rotation induced
by apomorphine. Some of them even almost recovered to
the levels of sham rats. Our results suggested that PF11
had potent anti-Parkinson property. The doses of PF11 were
selectedinthepresentstudyaccordingtoourpreviousstudies
w h i c hs h o w e dt h a tP F 1 1h a dp r o t e c t i v ee ff e c to nm e m o r y
impairment [18]. Our previous studies have proved that
PF11 can antagonize the decreases in striatal DA levels in
mice induced by methamphetamine [16]. It is reported that
methamphetamineanditsderivativesmaybeoneofthemain
causesofPDobservedinabusersofthesesubstances,because
of their neurotoxicity [16]. Acute administration of a high
dose or multiple administration of methamphetamine in a
short period can induce tardive dyskinetic movements and
depletion of DA content from dopaminergic neurons in man
[16]. It is suggested that PF11 possibly has anti-Parkinson
property through improving the function of dopaminergic
nerve. In the present study, PF11 was found to increase
significantlystriatalextracellularDAlevelandtheexpression
of TH in SN in PD rats. Tyrosine hydroxylase is usually
thought to be a rate-limiting enzyme in the synthesis of DA,
and its expression is the marker for the DA neuron survival.
Combined with previous studies and our present study, it isEvidence-Based Complementary and Alternative Medicine 7
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Figure 8: Effect of PF11 on the TH immunoreactive neurons in the
l e ftS No f6 - O H D A - l e s i o n e dr a t s .P h o t o m i c r o g r a p h ss h o w e dt h e
morphology of the SN neurons in the sham rats, 6-OHDA-lesioned
rats,PF11 -treatedrats(3,6,and12mg/kg),andMadopar-treatedrats.
The magnification was 400X. Results were means ± SEM of the data
obtained in six rats per group.
∗𝑃 < 0.05 compared to sham group;
#𝑃 < 0.05,
###𝑃 < 0.001 compared to 6-OHDA-lesioned group.
suggested that PF11 may have the neuroprotective action on
PD by improving degeneration of dopaminergic neurons in
t h eS Na n dD Ad e p l e t i o ni nt h es t r i a t u m .
In order to explore the possible mechanism about the
effectofPF11onPD,wedetectedthecontentsofstriatalextra-
cellular2,3-and2,5-DHBAandAA.Ithasbeendemonstrated
that dopaminergic neurons in PD are especially vulnerable
to oxygen free radicals [32]. Oxygen free radicals, especially
∙OH, may be a kind of important factor in the onset and/or
progressionofPDandmayfinallycontributetoneuronalcell
death [33]. 6-OHDA-induced dopaminergic neuron degen-
eration involves the processing of hydrogen peroxidase and
∙OH [34]. Furthermore, it has been reported that 6-OHDA
lesion decreases striatal glutathione (GSH) and superoxide
dismutase (SOD) enzyme activity [35]a n di n c r e a s e sl e v e lo f
malondialdehyde [36]. Interestingly, endogenous 6-OHDA
has been found to be accumulated in patients with PD [37].
Taken together, in neurodegenerative processes, 6-OHDA
causes oxidative stress, induced by
∙OH formation, which
candamagemitochondriaandothercellularcomponentsand
ultimately causes dopaminergic neuron death [38]. Evidence
for the depletion of antioxidants and antioxidant enzymes
accounts for the oxidative stress associated with 6-OHDA
toxicity in PD [22]. Therefore, it is important to protect
DA neurons degeneration through increasing the function
of antioxidant defense systems. Our previous study showed
that PF11 restored the activities of SOD and glutathione
peroxidase (GSH-Px) and decreased the production of mal-
ondialdehyde (MDA) in the cortex of APP/PS1 mice [13]. It
suggests that enhancing the function of antioxidant system
m a yb eo n eo ft h em e c h a n i s m so ft h ec e n t r a ln e u r o p r o t e c -
tive effects of PF11. It is well known that AA, a classical
endogenous antioxidant, plays a major role in protecting
brain against oxidative damage in the central nervous system
[39,40].AAcandirectlyscavengeoxygen-ornitrogen-based
radicalspeciesgeneratedduringnormalcellularmetabolism.
At the millimolar concentrations present in neurons in vivo,
AA can effectively scavenge superoxide, a major diffusible
byproduct of rapid neuronal mitochondrial metabolism [41],
and also compensate for loss of any other single component
of the antioxidant network [42].Consequently,itisespecially
important to study the change of AA level in PD rats. Our
study firstly found that the level of striatal AA was signif-
icantly decreased in PD rats, and PF11 markedly increased
the content of striatal AA. In recent years, AA has been
consideredasaneuromodulatororneuroprotectantandplays
a significant role in normal neuronal physiology [39]. For
instance,AAinvolvesinthesynthesisofDAandalsoinduces
synaptic maturation of the neurons [41]. These ascorbate
effects are not mimicked by other antioxidants, such as GSH
and vitamin E [41].OurstudyindicatedthattheeffectofPF11
o ntheincr easeo fD Ar eleaseandtheexp r essio no fTHmigh t
be due to the increase of AA which could protect the DA
neurons.
AA depletion might cause inability to scavenge free
radicals resulting in lipid peroxidation, leading to more
oxidant load and further oxidative damage [41]. To observe
the change of
∙OH after PF11 treatment in PD model, we
detectedthelevelsof2,3-and2,5-DHBA,whichwerethought
to be the sensitive assays for
∙OH formation both in vitro and
in vivo [8] by using microanalysis coupled with HPLC-ECD.
We found that the levels of striatal extracellular 2,3- and 2,5-
DHBA were much higher in PD rats than those in the sham
rats. PF11 treatment significantly reduced the increase of 2,3-
a n d2 , 5 - D H B Ai nt h es t r i a t u m .Th ea b o v er e s u l t sa b o u t
∙OH8 Evidence-Based Complementary and Alternative Medicine
and AA suggested that PF11 protected dopaminergic nerve
damage induced by 6-OHDA possibly via direct free radical
scavenging or indirect free radical scavenging by enhancing
the function of AA.
It should be noticed that several pathogeneses are
involved in PD [2]. For example, glutamate excitation and
neuroinflammation induced by 6-OHDA are the important
factors involved in the pathogenesis of PD [3]. Our previous
experiments have shown that PF11 improves the change of
glutamicacidinthemedialprefrontalcortexofmiceinduced
by morphine [17] and has antiamnesic effect in mouse
model of Alzheimer’s disease through antioxidation and
antiapoptosis [13]. Moreover, it is reported that ginsenoside
Rd inhibitstheneuroinflammationofdopaminergicneurons
evoked by lipopolysaccharide exposure [43]. Whether the
neuroprotective effect of PF11 on PD is related to glutamate
and neuroinflammation, needs to be studied in detail in the
future.
In conclusion, our results showed that PF11 reduced the
loss of nigral dopaminergic neurons, promoted the release
of striatal DA, and subsequently improved the abnormal
behaviors in PD rat model. Furthermore, PF11 treatment
significantly reduced the DHBA level and increased the
content of striatal AA in PD rats, indicating that PF11 had
neuroprotective effect on 6-OHDA-induced PD through
scavenging directly free radical and enhancing the antioxi-
dant ability. PF11 may serve as a promising clinical agent in
the treatment of PD.
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